You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

Details for New Drug Application (NDA): 022058


✉ Email this page to a colleague

« Back to Dashboard


NDA 022058 describes SUPPRELIN LA, which is a drug marketed by Endo Pharm and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the SUPPRELIN LA profile page.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.
Summary for 022058
Tradename:SUPPRELIN LA
Applicant:Endo Pharm
Ingredient:histrelin acetate
Patents:1
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 022058
Generic Entry Date for 022058*:
Constraining patent/regulatory exclusivity:
Dosage:
IMPLANT;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022058
Suppliers and Packaging for NDA: 022058
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058 NDA Endo Pharmaceuticals Inc. 67979-002 67979-002-01 1 VIAL, GLASS in 1 CARTON (67979-002-01) / 1 IMPLANT in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:IMPLANT;SUBCUTANEOUSStrength50MG
Approval Date:May 3, 2007TE:RLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Jun 16, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

Expired US Patents for NDA 022058

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 ⤷  Try a Trial ⤷  Try a Trial
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.